- Home
- MARPS vs RDHL Comparison
MARPS vs RDHL Comparison
Compare MARPS & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- RDHL
- Stock Information
- Founded
- MARPS 1956
- RDHL 2009
- Country
- MARPS United States
- RDHL Israel
- Employees
- MARPS N/A
- RDHL N/A
- Industry
- MARPS Oil & Gas Production
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- MARPS Energy
- RDHL Health Care
- Exchange
- MARPS Nasdaq
- RDHL Nasdaq
- Market Cap
- MARPS 8.6M
- RDHL 3.9M
- IPO Year
- MARPS N/A
- RDHL N/A
- Fundamental
- Price
- MARPS $4.64
- RDHL $1.50
- Analyst Decision
- MARPS
- RDHL
- Analyst Count
- MARPS 0
- RDHL 0
- Target Price
- MARPS N/A
- RDHL N/A
- AVG Volume (30 Days)
- MARPS 5.9K
- RDHL 88.3K
- Earning Date
- MARPS 01-01-0001
- RDHL 09-05-2025
- Dividend Yield
- MARPS 7.83%
- RDHL N/A
- EPS Growth
- MARPS N/A
- RDHL N/A
- EPS
- MARPS 0.36
- RDHL N/A
- Revenue
- MARPS $1,036,019.00
- RDHL $9,550,000.00
- Revenue This Year
- MARPS N/A
- RDHL $381.91
- Revenue Next Year
- MARPS N/A
- RDHL N/A
- P/E Ratio
- MARPS $12.73
- RDHL N/A
- Revenue Growth
- MARPS N/A
- RDHL 157.62
- 52 Week Low
- MARPS $3.34
- RDHL $1.06
- 52 Week High
- MARPS $7.90
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- MARPS 50.76
- RDHL 53.60
- Support Level
- MARPS $4.35
- RDHL $1.22
- Resistance Level
- MARPS $4.68
- RDHL $1.60
- Average True Range (ATR)
- MARPS 0.12
- RDHL 0.08
- MACD
- MARPS -0.02
- RDHL 0.04
- Stochastic Oscillator
- MARPS 40.85
- RDHL 73.68
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.